Acadian Asset Management LLC Buys 238,659 Shares of Aclaris Therapeutics, Inc. $ACRS

Acadian Asset Management LLC grew its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 10.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 2,433,850 shares of the biotechnology company’s stock after acquiring an additional 238,659 shares during the period. Acadian Asset Management LLC owned 2.25% of Aclaris Therapeutics worth $3,453,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. CRA Financial Services LLC bought a new stake in Aclaris Therapeutics during the 2nd quarter worth $25,000. Goldman Sachs Group Inc. grew its holdings in shares of Aclaris Therapeutics by 29.7% during the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock worth $851,000 after purchasing an additional 127,366 shares during the last quarter. Millennium Management LLC increased its stake in shares of Aclaris Therapeutics by 111.0% in the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares during the period. Palo Alto Investors LP increased its stake in shares of Aclaris Therapeutics by 36.2% in the first quarter. Palo Alto Investors LP now owns 776,028 shares of the biotechnology company’s stock valued at $1,187,000 after buying an additional 206,196 shares during the period. Finally, State of Wyoming bought a new position in Aclaris Therapeutics in the 1st quarter valued at approximately $72,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Wall Street Analysts Forecast Growth

ACRS has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a report on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.71.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $2.52 on Friday. Aclaris Therapeutics, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $5.17. The company has a 50 day simple moving average of $2.08 and a two-hundred day simple moving average of $1.73. The company has a market capitalization of $273.03 million, a PE ratio of -1.84 and a beta of 0.43.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. Aclaris Therapeutics had a negative net margin of 802.03% and a negative return on equity of 34.01%. The company had revenue of $3.30 million for the quarter, compared to analyst estimates of $1.59 million. Research analysts predict that Aclaris Therapeutics, Inc. will post -0.82 EPS for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.